Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Virchows Archiv
Published in: Virchows Archiv 5/2009

01-05-2009 | Original Article

Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer

Authors: M. Graeser, K. Bosse, M. Brosig, C. Engel, R. K. Schmutzler, on behalf of the German Consortium for Hereditary Breast and Ovarian Cancer

Published in: Virchows Archiv | Issue 5/2009

Login to get access

Abstract

BRCA1-associated breast cancer frequently presents with estrogen-receptor (ERα) and progesterone-receptor (PR) negativity, grade 3, and early onset. In contrast, in BRCA1-deficient mice, ERα is highly expressed in early tumorigenesis. In a retrospective cohort study on 587 breast cancer patients with deleterious BRCA1 mutations, the correlation of ER, PR status, grading, age of onset, and tumor size was investigated. ERα and PR expression decreased from 62% in ductal carcinoma in situ (DCIS) to 20% and 16% in pT3, respectively (p value for ER 0.025 and PR 0.035, Fisher’s exact test). The percentage of grade 1/2 tumors decreased from 44% in DCIS to 17% in pT3 (p value 0.074). Moreover, ER/PR positivity increased with increasing age. Our data suggest that early stage BRCA1-associated breast cancers are more frequently ERα and PR positive and low grade than advanced stages.
Literature
1.
Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676–689PubMedCrossRef
2.
Ford D, Easton DF, Bishop DT et al (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343:692–695PubMedCrossRef
3.
Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71PubMedCrossRef
4.
Turner N, Tutt A, Ashworth A (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4:814–819PubMedCrossRef
5.
Fan S, Wang J, Yuan R et al (1999) BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284:1354–1356PubMedCrossRef
6.
Razandi M, Pedram A, Rosen EM et al (2004) BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. Mol Cell Biol 4:5900–5913CrossRef
7.
Korach KS (1994) Insights from the study of animals lacking functional estrogen receptor. Science 266:1524–1527PubMedCrossRef
8.
Li X, Lonard DM, O'Malley BW (2004) A contemporary understanding of progesterone receptor function. Mech Ageing Dev 125:669–678PubMedCrossRef
9.
Ma Y, Katiyar P, Jones LP et al (2006) The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol 20:14–34PubMedCrossRef
10.
Zheng L, Annab LA, Afshari CA et al (2001) BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci USA 98:9587–9592PubMedCrossRef
11.
Li W, Xiao C, Vonderhaar BK et al (2007) A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation. Oncogene 26:7204–7212PubMedCrossRef
12.
Johannsson OT, Idvall I, Anderson C et al (1997) Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33:362–371PubMedCrossRef
13.
Eisinger F, Jacquemier J, Nogues C et al (1999) Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 1585:2291–2295CrossRef
14.
Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622PubMedCrossRef
15.
Narod SA, Brunet JS, Ghadirian P et al (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356:1876–1881PubMedCrossRef
16.
King TA, Gemignani ML, Li W et al (2004) Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers. Cancer Res 64:5051–5053PubMedCrossRef
17.
Poole AJ, Li Y, Kim Y et al (2006) Prevention of BRCA1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314:1467–1470PubMedCrossRef
18.
Meindl A (2002) Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 97:472–480PubMedCrossRef
19.
Remmele W, Schicketanz KH (1993) Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 189:862–866PubMed
20.
Atchley DP, Albarracin CT, Lopez A et al (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 1026:4282–4288CrossRef
21.
Foulkes WD, Metcalfe K, Sun P et al (2004) Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10:2029–2034PubMedCrossRef
22.
Vaziri SA, Krumroy LM, Elson P et al (2001) Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res 7:1937–1945PubMed
23.
Metcalfe K, Lynch HT, Ghadirian P et al (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328–2335PubMedCrossRef
24.
Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615PubMedCrossRef
25.
Jones LP, Li M, Halama ED et al (2005) Promotion of mammary cancer development by tamoxifen in a mouse model of BRCA1-mutation-related breast cancer. Oncogene 24:3554–3562PubMedCrossRef
Metadata
Title
Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer
Authors
M. Graeser
K. Bosse
M. Brosig
C. Engel
R. K. Schmutzler
on behalf of the German Consortium for Hereditary Breast and Ovarian Cancer
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
Virchows Archiv / Issue 5/2009
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-009-0760-8

Other articles of this Issue 5/2009

Virchows Archiv 5/2009 Go to the issue

Original Article

Semaphorin3A immunohistochemical expression in human meningiomas: correlation with the microvessel density

Original Article

Histopathology report of cutaneous melanoma and sentinel lymph node in Europe: a web-based survey by the Dermatopathology Working Group of the European Society of Pathology

Review and Perspective

Mitochondria and cancer

Original Article

βIII-tubulin at the invasive margin of colorectal cancer: possible link to invasion

Case Report

Leiomyomatous nodules in a cellular angiofibroma: a hitherto unreported finding

Original Article

Unison or cacophony: postgraduate training in pathology in Europe